Alfred B Ordman

US Patent:

20080171791, Jul 17, 2008

Filed:

Jan 11, 2008

Appl. No.:

12/013105

Inventors:

Alfred B. Ordman - Monticello WI, US

Assignee:

MDR Fitness Corp. - Sunrise FL

International Classification:

A61K 31/201
A61K 31/198

US Classification:

514560, 514561

Abstract:

Methods and compositions for assisting in human weight loss. In a preferred embodiment, the administration of branched-chain amino acids and fatty acids to a subject at a level that provides approximately a two and a half percent (2.5%) reduction in weight over a one-week period.

US Patent:

55588700, Sep 24, 1996

Filed:

Oct 3, 1994

Appl. No.:

8/317311

Inventors:

Alfred B. Ordman - Beloit WI

International Classification:

A61K 920

US Classification:

424400

Abstract:

A method of administration of vitamin C to ensure that a continuously-saturated level is produced in the body of a taker. A dose of about 500 mg taken approximately every 12 hours produces a continuously-detectable level of vitamin C in the urine of an average healthy person, which corresponds to a sufficiently high pool of ascorbic acid in the body to provide anti-oxidant protection. The minimum dosage and regimen found to be effective are respectively substantially higher than the U. S. recommended daily allowance and more frequent than administration rates previously used in clinical trials. Also claimed are kits that permit individuals to monitor for elevated urinary excretion of useful substances which are water soluble, excreted in urine, and non-toxic at physiologically beneficial levels, such that optimal dosages and regimens can be determined.

US Patent:

57831505, Jul 21, 1998

Filed:

Sep 10, 1996

Appl. No.:

8/709257

Inventors:

Alfred B. Ordman - Beloit WI

International Classification:

G01N 3348

US Classification:

422 61

Abstract:

A method of administration of vitamin C to ensure that a continuously-saturated level is produced in the body of a taker. A dose of about 500 mg taken approximately every 12 hours produces a continuously-detectable level of vitamin C in the urine of an average healthy person, which corresponds to a sufficiently high pool of ascorbic acid in the body to provide anti-oxidant protection. The minimum dosage and regimen found to be effective are respectively substantially higher than the U. S. recommended daily allowance and more frequent than administration rates previously used in clinical trials. Also claimed are kits that permit individuals to monitor for elevated urinary excretion of useful substances which are water soluble, excreted in urine, and non-toxic at physiologically beneficial levels, such that optimal dosages and regimens can be determined.

US Patent:

59322268, Aug 3, 1999

Filed:

Sep 10, 1996

Appl. No.:

8/709258

Inventors:

Alfred B. Ordman - Beloit WI

International Classification:

A61K 920
A61K 31375
A61K 4500

US Classification:

424400

Abstract:

A test kit and method for determining the optimal level of intake for an individual of a useful substance--including vitamin C and calcium--that is water soluble, urine excretable, and nontoxic at physiologically beneficial levels is disclosed.

US Patent:

20210315928, Oct 14, 2021

Filed:

Jun 24, 2021

Appl. No.:

17/357651

Inventors:

ALFRED ORDMAN - ROCKFORD IL, US

International Classification:

A61K 33/24
A61K 31/122
A61K 31/375

Abstract:

The present invention relates to a pharmaceutical composition comprising vitamin C, or pharmaceutically acceptable salt, solvate or hydrate thereof, in combination with vitamin K1, or pharmaceutically acceptable salt, solvate or hydrate thereof, and may or may not include chromium, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and a pharmaceutically acceptable carrier. Further provided herein is the method of treating, managing, or preventing cancer in human comprising administering a predetermined dosage of pharmaceutical composition comprising Vitamin C or pharmaceutically acceptable salts thereof and Vitamin K1 or a pharmaceutically acceptable salt thereof and may or may not include chromium, or a pharmaceutically acceptable salt, solvate, or hydrate thereof at a predetermined time.

US Patent:

20200397739, Dec 24, 2020

Filed:

Aug 31, 2020

Appl. No.:

17/007587

Inventors:

ALFRED ORDMAN - ROCKFORD IL, US

International Classification:

A61K 31/341
A61K 33/24
A61K 31/122

Abstract:

The present invention relates to a pharmaceutical composition comprising vitamin C, or pharmaceutically acceptable salt, solvate or hydrate thereof, in combination with vitamin K1, or pharmaceutically acceptable salt, solvate or hydrate thereof, and may or may not include chromium, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and a pharmaceutically acceptable carrier. Further provided herein is the method of treating, managing, or preventing cancer in human comprising administering a predetermined dosage of pharmaceutical composition comprising Vitamin C or pharmaceutically acceptable salts thereof and Vitamin K1 or a pharmaceutically acceptable salt thereof and may or may not include chromium, or a pharmaceutically acceptable salt, solvate, or hydrate thereof at a predetermined time.

US Patent:

20200237710, Jul 30, 2020

Filed:

Jan 23, 2020

Appl. No.:

16/750952

Inventors:

ALFRED ORDMAN - ROCKFORD IL, US

International Classification:

A61K 31/341
A61K 31/122
A61K 33/24

Abstract:

The present invention relates to a pharmaceutical composition comprising vitamin C, or pharmaceutically acceptable salt, solvate or hydrate thereof, in combination with vitamin K1, or pharmaceutically acceptable salt, solvate or hydrate thereof, and may or may not include chromium, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and a pharmaceutically acceptable carrier. Further provided herein is the method of treating, managing, or preventing cancer in human comprising administering a predetermined dosage of pharmaceutical composition comprising Vitamin C or pharmaceutically acceptable salts thereof and Vitamin K1 or a pharmaceutically acceptable salt thereof and may or may not include chromium, or a pharmaceutically acceptable salt, solvate, or hydrate thereof at a predetermined time.